Project Grant R01AI192937
- The National Institute of Allergy and Infectious Diseases awarded New York University $755,801 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the regulation of CD4+ and CD8+ T cell function by CLNS1A. The research examines the mechanisms controlling T lymphocyte function in immunity to infection and cancer, as well as in autoimmune and allergic diseases. The project uses forward genetics screens in animal models of brain and...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $3,144,408 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate regulatory T cell memory in human tissues. The award funds research to characterize the role, identity, and function of human regulatory T cells (Tregs) across diverse tissues and their interactions with immune and structural cells. The project will...
- The National Institute of Allergy and Infectious Diseases awarded New York University $508,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how myeloid cells, particularly neutrophils, regulate plasma membrane homeostasis to control decisions between functional immune programs including migration, phagocytosis, and netosis. The research, conducted as a postdoctoral project at New York University School of Medicine...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $822,280 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on intragraft alloreactive T cells in human solid organ transplantation, with the goal of controlling rejection after transplantation. The research dissects intragraft T cell alloimmunity using longitudinal surveillance biopsies from intestinal...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $552,000 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct functional characterization of dendritic cell heterogeneity for T cell-inducing immunotherapies. The research addresses vaccine development for intracellular pathogens including HIV/AIDS and malaria by investigating the distinct roles of type 1 and type 2 conventional dendritic cells in...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $100,228 on November 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into origin licensing and MCM complex regulation in human lymphocytes, specifically investigating lineage-specific differences in how natural killer cells and CD8+ memory T cells regulate cell cycle entry and respond to replication stress....
- The National Institute of Allergy and Infectious Diseases awarded Duke University $533,926 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the functional contributions of neonatal-origin CD4 T cells to adult immunity and tissue function. Duke will develop and leverage a novel timestamping system to track T cells originating during early life as they persist into adulthood, characterizing their breadth of innate responsiveness during...
- The National Institute of Allergy and Infectious Diseases awarded the University of Rochester $162,000 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on genome organization in dendritic cell development. The project, titled "Elucidating the Role of Genome Organization in CDC1 Development," investigates how the cohesin protein complex controls the epigenetic regulation of type 1 conventional dendritic cell (CDC1)...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded New York University $808,523 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate T follicular helper (TFH) cell development and calcium signaling in humoral immunity. The research examines how calcium ions flowing through CRAC channels regulate chromatin accessibility and transcription...
- The National Institute of Allergy and Infectious Diseases awarded New York University a project grant of $466,125 on January 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of CD69 in established resident memory T cells. The research examines why resident memory T cells (TRM)—which persist at infection sites long after disease resolution—express high levels of CD69, a membrane-bound protein typically associated with early T cell...
The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $622,850 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the heterogeneous functions, antigen specificities, and lipid antigen restrictions of human CD4-/CD8- double-negative T cells (DN T cells). The research examines how CD1-restricted DN T cell populations respond to CD1-presented self-lipid antigens and determines their roles across autoimmune disease, graft versus host disease, tumor immunology, and engineered cell therapies. The award is structured as a Project Grant with a performance period through August 31, 2031, and work is performed in New York, NY 10032, USA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $622.9k | 9/2/26 |